{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T09:06:00Z","timestamp":1785229560759,"version":"3.55.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The mechanism related to docetaxel resistance in PCa has not been fully elucidated, and in-depth study of the specific mechanism of docetaxel resistance in PCa is of great clinical significance for the treatment of PCa.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We explored the expression level of PIGL and HUWE1 using TCGA database and our clinical sample. CCK8 assay, Transwell assay, colony formation assay, wound-healing assay were used to explore the role of HUWE1\/PIGL. Ubiquitination assay and Co-immunoprecipitation assay were used to investigate the molecular mechanism.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We found that both the mRNA and protein of PIGL is highly expressed in prostate cancer (PCa) and associated with poor prognosis. The protein rather than mRNA of PIGL is highly expressed in docetaxel-resistant PCa and associated with prognosis in patients receiving docetaxel-based chemotherapy. High expression level of PIGL promotes the proliferation, migration, invasion, and docetaxel resistance of PCa cells\n                      <jats:italic>in vitro<\/jats:italic>\n                      . Mass spectrometry after immunoprecipitation identified HUWE1 as a binding protein of PIGL. The protein of HUWE1 is lowly expressed in docetaxel-resistant PCa and associated with prognosis in patients receiving docetaxel-based chemotherapy. HUWE1 might be served as the E3 ubiquitin ligase of PIGL and negatively regulated the expression of PIGL protein rather than mRNA. The knockdown of HUWE1 could promote the docetaxel resistance of PCa and could be rescued by PIGL silencing.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>These findings emphasized the vital role of PIGL in the progression and docetaxel resistance of PCa and the effect of the E3 ubiquitin ligase HUWE1 on regulating the protein expression of PIGL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1740132","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T05:30:18Z","timestamp":1781760618000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["PIGL promotes the docetaxel resistance of prostate cancer and is regulated by E3 ubiquitin ligase HUWE1"],"prefix":"10.3389","volume":"17","author":[{"given":"Pan","family":"Gao","sequence":"first","affiliation":[{"name":"Department of Urology, Urology Research Institute, The First Affiliated Hospital, Fujian Medical University","place":["Fuzhou, China"]},{"name":"Department of Urology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University","place":["Fuzhou, China"]},{"name":"Department of Urology, Second People\u2019s Hospital of Yichang","place":["Yichang, China"]},{"name":"Department of Urology, Second People\u2019s Hospital of China Three Gorges University","place":["Yichang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-Han","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Urology, Urology Research Institute, The First Affiliated Hospital, Fujian Medical University","place":["Fuzhou, China"]},{"name":"Department of Urology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, Second People\u2019s Hospital of Yichang","place":["Yichang, China"]},{"name":"Department of Urology, Second People\u2019s Hospital of China Three Gorges University","place":["Yichang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze-Yu","family":"Yi","sequence":"additional","affiliation":[{"name":"Department of Urology, Urology Research Institute, The First Affiliated Hospital, Fujian Medical University","place":["Fuzhou, China"]},{"name":"Department of Urology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Bin","family":"Ke","sequence":"additional","affiliation":[{"name":"Department of Urology, Urology Research Institute, The First Affiliated Hospital, Fujian Medical University","place":["Fuzhou, China"]},{"name":"Department of Urology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong-Hua","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Urology, Urology Research Institute, The First Affiliated Hospital, Fujian Medical University","place":["Fuzhou, China"]},{"name":"Department of Urology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Urology, The First People\u2019s Hospital of Yunnan Province","place":["Kunming, China"]},{"name":"Department of Urology, The Affiliated Hospital of Kunming University of Science and Technology","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Urology, Urology Research Institute, The First Affiliated Hospital, Fujian Medical University","place":["Fuzhou, China"]},{"name":"Department of Urology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215927","article-title":"Prostate cancer treatment - China's perspective","volume":"550","author":"Liu","year":"2022","journal-title":"Cancer Lett"},{"key":"B2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2135-x","article-title":"A genomic and epigenomic atlas of prostate cancer in Asian populations","volume":"580","author":"Li","year":"2020","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s11356-022-24266-0","article-title":"Analysis of the distribution characteristics of prostate cancer and its environmental factors in China","volume":"30","author":"Zhang","year":"2023","journal-title":"Environ Sci pollut Res Int"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1172\/jci183583","article-title":"Survival of men with metastatic hormone-sensitive prostate cancer and adrenal-permissive HSD3B1 inheritance","volume":"34","author":"Sharifi","year":"2024","journal-title":"J Clin Invest"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3895","article-title":"Patient-reported outcomes following neoadjuvant endocrine therapy, external beam radiation, and adjuvant continuous\/intermittent endocrine therapy for locally advanced prostate cancer: a randomized phase III trial","volume":"10","author":"Yokomizo","year":"2021","journal-title":"Cancer Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.126319","article-title":"OTUB2\/ALYREF axis modulates the docetaxel resistance of castration-resistant prostate cancer via upregulating ABCG4-mediated drug efflux","volume":"22","author":"Ke","year":"2026","journal-title":"Int J Biol Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2020.100742","article-title":"Taxanes in cancer treatment: activity, chemoresistance and its overcoming","volume":"54","author":"Mosca","year":"2021","journal-title":"Drug Resist Update"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/ju.0000000000003876","article-title":"A prospective randomized trial of neoadjuvant chemohormonal therapy vs hormonal therapy in locally advanced prostate cancer treated by radical prostatectomy","volume":"211","author":"Qian","year":"2024","journal-title":"J Urol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-022-06047-6","article-title":"Head-to-head comparisons of [(68)Ga]Ga-PSMA-11 PET\/CT, multiparametric MRI, and prostate-specific antigen for the evaluation of therapeutic responses to neoadjuvant chemohormonal therapy in high-risk non-metastatic prostate cancer patients: a prospective study","volume":"50","author":"Ke","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-023-01048-3","article-title":"Elevated nuclear PIGL disrupts the cMyc\/BRD4 axis and improves PD-1 blockade therapy by dampening tumor immune evasion","volume":"20","author":"Yu","year":"2023","journal-title":"Cell Mol Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.1c00465","article-title":"Rescue of glycosylphosphatidylinositol-anchored protein biosynthesis using synthetic glycosylphosphatidylinositol oligosaccharides","volume":"16","author":"Guerrero","year":"2021","journal-title":"ACS Chem Biol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41418-020-00708-5","article-title":"Ubiquitination in the regulation of inflammatory cell death and cancer","volume":"28","author":"Cockram","year":"2021","journal-title":"Cell Death Differ"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyaf082","article-title":"Stage-standardized and stage-specific survival among men with prostate cancer in the Nordic countries 2004-16: the NORDCAN survival studies","volume":"54","author":"Larsen","year":"2025","journal-title":"Int J Epidemiol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-025-01317-5","article-title":"PSMA-based therapies and novel therapies in advanced prostate cancer: the now and the future","volume":"26","author":"Ayzman","year":"2025","journal-title":"Curr Treat Options Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/antiox10121925","article-title":"Radioresistance in prostate cancer: focus on the interplay between NF-\u03baB and SOD","volume":"10","author":"Kumar","year":"2021","journal-title":"Antioxidants (Basel)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103625","article-title":"Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase","volume":"72","author":"Lin","year":"2021","journal-title":"EBioMedicine"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-20-3845","article-title":"Loss of long noncoding RNA NXTAR in prostate cancer augments androgen receptor expression and enzalutamide resistance","volume":"82","author":"Ghildiyal","year":"2022","journal-title":"Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.4103\/aja.aja_40_17","article-title":"Role of chemotherapy in prostate cancer","volume":"20","author":"Nader","year":"2018","journal-title":"Asian J Androl"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2013.08.004","article-title":"Neoadjuvant and adjuvant hormonal and chemotherapy for prostate cancer","volume":"27","author":"Lam","year":"2013","journal-title":"Hematol Oncol Clin North Am"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24134","article-title":"Impact of therapy on cancer metabolism in high-risk localized prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy","volume":"81","author":"Qu","year":"2021","journal-title":"Prostate"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.41686","article-title":"Quercetin reverses docetaxel resistance in prostate cancer via androgen receptor and PI3K\/Akt signaling pathways","volume":"16","author":"Lu","year":"2020","journal-title":"Int J Biol Sci"},{"key":"B23","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s12032-021-01566-y","article-title":"Suppressed PLIN3 frequently occurs in prostate cancer, promoting docetaxel resistance via intensified autophagy, an event reversed by chloroquine","volume":"38","author":"Lamprou","year":"2021","journal-title":"Med Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2025.101227","article-title":"TGF\u03b2-activated Asporin interacts with STMN1 to promote prostate cancer docetaxel chemoresistance and metastasis by upregulating the Wnt\/\u03b2-catenin signaling pathway","volume":"81","author":"Ge","year":"2025","journal-title":"Drug Resist Update"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-4776981\/v1","article-title":"AGD1\/USP10\/METTL13 complexes enhance cancer stem cells proliferation and diminish the therapeutic effect of docetaxel via CD44 m6A modification in castration resistant prostate cancer","volume":"44","author":"Wang","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/s41419-024-07117-3","article-title":"USP3 promotes DNA damage response and chemotherapy resistance through stabilizing and deubiquitinating SMARCA5 in prostate cancer","volume":"15","author":"Li","year":"2024","journal-title":"Cell Death Dis"},{"key":"B27","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12943-024-01994-0","article-title":"Co-transcriptional R-loops-mediated epigenetic regulation drives growth retardation and docetaxel chemosensitivity enhancement in advanced prostate cancer","volume":"23","author":"Ying","year":"2024","journal-title":"Mol Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1600420113","article-title":"Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression","volume":"113","author":"Komura","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.38181","article-title":"Alu-mediated deletion of PIGL in a patient with CHIME syndrome","volume":"173","author":"Knight Johnson","year":"2017","journal-title":"Am J Med Genet A"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-022-00957-6","article-title":"Ubiquitin ligase E3 HUWE1\/MULE targets transferrin receptor for degradation and suppresses ferroptosis in acute liver injury","volume":"29","author":"Wu","year":"2022","journal-title":"Cell Death Differ"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.mcr-16-0346","article-title":"R1 regulates prostate tumor growth and progression by transcriptional suppression of the E3 ligase HUWE1 to stabilize c-Myc","volume":"16","author":"Lin","year":"2018","journal-title":"Mol Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2018.06.058","article-title":"HUWE1 upregulation has tumor suppressive effect in human prostate cancer cell lines through c-Myc","volume":"106","author":"Qu","year":"2018","journal-title":"BioMed Pharmacother"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2015.309","article-title":"Regulation of c-Myc expression by the histone demethylase JMJD1A is essential for prostate cancer cell growth and survival","volume":"35","author":"Fan","year":"2016","journal-title":"Oncogene"},{"key":"B34","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/s41419-020-2405-4","article-title":"Histone demethylase JMJD1A promotes expression of DNA repair factors and radio-resistance of prostate cancer cells","volume":"11","author":"Fan","year":"2020","journal-title":"Cell Death Dis"}],"updated-by":[{"DOI":"10.3389\/fimmu.2026.1933318","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000}}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1740132\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T08:56:38Z","timestamp":1785228998000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1740132\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":34,"alternative-id":["10.3389\/fimmu.2026.1740132"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1740132","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"article-number":"1740132"}}